Elanco Animal Health (ELAN) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Elanco Animal Health (ELAN) over the past year, gaining 114.3% versus a gain of 10.8%. Over five years, PTGX leads with a +351.8% price change compared with -30.7% for ELAN. Elanco Animal Health is the larger company by market cap ($11.26 billion vs $9.05 billion), about 1.2 times the size.
Elanco Animal Health converts more of its revenue into profit, with a net margin of -4.9% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELAN | PTGX |
|---|---|---|
| Share price | $22.54 | $139.91 |
| Market cap | $11.26B | $9.05B |
| 1-day change | +0.81% | -0.72% |
| YTD return | -0.40% | +60.19% |
| 1-year return | +10.82% | +114.26% |
| 5-year return | -30.73% | +351.76% |
| P/E ratio (TTM) | — | 135.83 |
| Forward P/E | 17.54 | — |
| EPS (TTM) | $-0.41 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.71B | $46.02M |
| Revenue growth (YoY) | +6.22% | -89.41% |
| Net income (latest FY) | $-232.00M | $-130.15M |
| Gross margin | 54.99% | — |
| Operating margin | — | -343.63% |
| Net margin | -4.92% | -282.83% |
| 52-week high | $27.98 | $160.81 |
| 52-week low | $19.40 | $65.75 |
| Distance from 52-week high | -19.44% | -13.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +37.53% | +24.86% |
| Average volume | 6.19M | 623.06K |
| Shares outstanding | 499.45M | 64.71M |
| Employees | 9,400 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed ELAN by 103.4 percentage points over the past year.
- Elanco Animal Health is more profitable, keeping -4.9 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- Elanco Animal Health grew revenue faster in its latest fiscal year (+6.22% vs -89.41%).
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
ELAN vs PTGX FAQ
Which is bigger, Elanco Animal Health or Protagonist Therapeutics?
Elanco Animal Health (ELAN) is larger, with a market capitalization of $11.26B compared with $9.05B for Protagonist Therapeutics (PTGX).
Which stock has performed better over the past year, ELAN or PTGX?
PTGX returned +114.26% over the past 12 months, compared with +10.82% for ELAN (price return, excluding dividends). Past performance does not predict future results.
Are Elanco Animal Health and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.